1. Home
  2. HAWK vs KARD Comparison

HAWK vs KARD Comparison

Compare HAWK & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HawkEye 360 Inc. Common Stock

HAWK

HawkEye 360 Inc. Common Stock

N/A

Current Price

$14.63

Market Cap

2.0B

Sector

Technology

ML Signal

N/A

Logo Kardigan Inc. Common Stock

KARD

Kardigan Inc. Common Stock

N/A

Current Price

$14.11

Market Cap

1.9B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
HAWK
KARD
Founded
2015
2023
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.9B
IPO Year
2026
2026

Fundamental Metrics

Financial Performance
Metric
HAWK
KARD
Price
$14.63
$14.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
4
Target Price
$32.56
★ $42.25
AVG Volume (30 Days)
★ 1.2M
500.6K
Earning Date
11-12-2026
08-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$84.87
N/A
Revenue Next Year
$24.92
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.21
$13.75
52 Week High
$25.71
$27.00

Technical Indicators

Market Signals
Indicator
HAWK
KARD
Relative Strength Index (RSI) 28.61 32.59
Support Level N/A $13.75
Resistance Level $17.42 $22.81
Average True Range (ATR) 0.68 1.22
MACD 0.02 -0.15
Stochastic Oscillator 2.26 21.59

Price Performance

Historical Comparison
HAWK
KARD

About HAWK HawkEye 360 Inc. Common Stock

Hawkeye 360 Inc operates in the signals intelligence (SIGINT) and defense technology sector. It provides end-to-end signals intelligence solutions integrated into national security systems for the United States and allied customers. Its offerings include radio frequency data and related insights to support defense operations. The company is involved across the value chain, including satellite design and manufacturing, data collection, and data processing and analysis. It generates revenue prominently from fixed price contract arrangements for RF signal mapping products that are used to analyze and track radio waves.

About KARD Kardigan Inc. Common Stock

Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.

Share on Social Networks: